Medtronic plc.

As of July 31, 2026, Medtronic Plc carries a market capitalization of 109.75B, placing it among publicly traded companies globally. Its enterprise value stands at 129.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medtronic Plc's next confirmed earnings release is scheduled for November 24, 2026.

As of July 31, 2026, Medtronic Plc has 1.28B shares outstanding.

As of July 31, 2026, Medtronic Plc trades at a trailing price-to-earnings ratio of 21.00. The price-to-sales ratio is 2.93, and the price-to-book ratio stands at 2.18.

As of July 31, 2026, Medtronic Plc trades at an EV/EBITDA multiple of 13.34 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.11 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medtronic Plc trades at an EV/FCF ratio of 19.33, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 129.70B versus a market cap of 109.75B, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, Medtronic Plc maintains a current ratio of 2.07, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.36, indicating elevated leverage, while an interest coverage ratio of 13.43 demonstrates strong ability to service its debt obligations.

Over the twelve months ended July 31, 2026, Medtronic Plc posted a return on equity (ROE) of 10.66, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.89 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.68, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.41, useful for judging operating efficiency across full business cycles. The company generates approximately 395,168.42 in revenue per employee across its workforce of 95,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.17 indicates how many times Medtronic Plc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended July 31, 2026, Medtronic Plc recorded 1.33B in income tax expense. That works out to an effective tax rate of 20.18, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.60B, leaving 5.23B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Medtronic Plc's stock has gained approximately 3.05% over the past 52 weeks. The 50-day moving average sits at 91.42, while the 200-day moving average is 88.46.

Over the twelve months ended July 31, 2026, Medtronic Plc generated 37.54B in revenue and converted that into 5.23B in net income, yielding earnings per share of 4.09. EBITDA reached 9.73B, while operating income came in at 7.15B.

As of July 31, 2026, Medtronic Plc holds 8.82B in cash and equivalents against 28.15B in total debt, resulting in a net debt position of 26.41B. Total book value stands at 50.23B, with working capital of 12.59B providing operational flexibility.

Medtronic Plc produced 8.04B in operating cash flow over the twelve months ended July 31, 2026. After subtracting -1.90B in capital expenditures, free cash flow totaled 6.13B - equivalent to 4.79 per share.

Over the twelve months ended July 31, 2026, Medtronic Plc posted a gross margin of 65.01, reflecting its pricing power and cost economics. The operating margin of 19.04 and net profit margin of 13.93 provide insight into operational efficiency.

Over the twelve months ended July 31, 2026, Medtronic Plc paid dividends of 2.85 per share. The dividend payout ratio of 68.78 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.55, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.38, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medtronic Plc shareholders.

Medtronic Plc's most recent stock split took place on September 27, 1999 with a 1:2 split ratio.

As of July 31, 2026, Medtronic Plc has an Altman Z-Score of 4.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.